Methods for treatment of interstitial cystitis

Abstract

The present application relates to methods and uses of CB2 target agent local anaesthetics such as beta-caryophyllene for treatment of interstitial cystitis in a subject, optionally together with the administration or use of an additional agent for treating interstitial cystitis such as dimethyl sulfoxide (DMSO) or methylsulfonylmethane (MSM).

1 . A method of treating interstitial cystitis in a subject, the method comprising administering a CB2 target agent local anaesthetic to the subject. 
     
     
         2 . The method of  claim 1 , wherein the CB2 target agent local anaesthetic is a CB2 orthosteric agonist agent local anaesthetic. 
     
     
         3 . The method of  claim 2 , wherein the CB2 orthosteric agonist agent local anaesthetic is beta-caryophyllene. 
     
     
         4 . The method of  claim 3 , further comprising administering an additional agent for treating interstitial cystitis in the subject. 
     
     
         5 . The method of  claim 4 , wherein the additional agent is dimethyl sulfoxide. 
     
     
         6 . The method of  claim 5 , wherein the dimethyl sulfoxide is administered intravesically as an aqueous solution comprising from about 5% to about 50% dimethyl sulfoxide. 
     
     
         7 . The method of  claim 6 , wherein the aqueous solution comprises about 5% dimethyl sulfoxide. 
     
     
         8 . The method of  claim 4 , wherein the additional agent is methylsulfonylmethane. 
     
     
         9 . The method of  claim 8 , wherein the methylsulfonylmethane is administered intravesically as an aqueous solution comprising about 5% methylsulfonylmethane. 
     
     
         10 . The method of  claim 8 , wherein the methylsulfonylmethane is administered orally. 
     
     
         11 . The method of  claim 3 , wherein the CB2 target agent local anaesthetic is administered orally. 
     
     
         12 . The method of  claim 11 , wherein the oral administration is in the form of a capsule comprising the CB2 target agent local anaesthetic. 
     
     
         13 . The method of  claim 12 , wherein the CB2 target agent local anaesthetic is administered in combination with methylsulfonylmethane and the capsule further comprises the methylsulfonylmethane. 
     
     
         14 . The method of  claim 3 , wherein the CB2 target agent local anaesthetic is administered topically. 
     
     
         15 . The method of  claim 14 , wherein the topical administration is in the form of a topical cream comprising the CB2 target agent local anaesthetic. 
     
     
         16 . The method of  claim 3 , wherein the CB2 target agent local anaesthetic is administered intravesically. 
     
     
         17 . The method of  claim 16 , wherein the CB2 target agent local anaesthetic is administered in combination with dimethyl sulfoxide and the intravesical administration is in the form of an aqueous solution comprising the CB2 target agent local anaesthetic and the dimethyl sulfoxide. 
     
     
         18 . The method of  claim 16 , wherein the CB2 target agent local anaesthetic is administered in combination with methylsulfonylmethane and the intravesical administration is in the form of an aqueous solution comprising the CB2 target agent local anaesthetic and the methylsulfonylmethane. 
     
     
         19 . The method of  claim 3 , wherein the subject is human. 
     
     
         20 . The method of  claim 19 , wherein the subject is female.